[ad_1]
The data – although it does confirm that the vaccine protects against severe cases and hospitalization – indicate that the effectiveness in preventing symptomatic cases fell by 30%, from 94.3% in May to 64% in June. compared to the Delta SARS-CoV-2 variant.
In all cases, the vaccine’s validity in preventing severe cases and hospitalizations is reiterated, although there was also a slight drop from 98.2% in May to 93% in June.
In Israel, 90% of new cases in the past two weeks are attributed to the Delta variant.
Source link